GR73519B - - Google Patents

Info

Publication number
GR73519B
GR73519B GR64674A GR810164647A GR73519B GR 73519 B GR73519 B GR 73519B GR 64674 A GR64674 A GR 64674A GR 810164647 A GR810164647 A GR 810164647A GR 73519 B GR73519 B GR 73519B
Authority
GR
Greece
Prior art keywords
active agent
compartment
dispensing
fluid
dispensed
Prior art date
Application number
GR64674A
Other languages
Greek (el)
English (en)
Inventor
Pieter Bonsen
Patrick Seck-Lai Wong
Felix Theeuwes
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of GR73519B publication Critical patent/GR73519B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR64674A 1980-04-25 1981-04-10 GR73519B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/143,644 US4265874A (en) 1980-04-25 1980-04-25 Method of delivering drug with aid of effervescent activity generated in environment of use

Publications (1)

Publication Number Publication Date
GR73519B true GR73519B (OSRAM) 1984-03-09

Family

ID=22504961

Family Applications (1)

Application Number Title Priority Date Filing Date
GR64674A GR73519B (OSRAM) 1980-04-25 1981-04-10

Country Status (11)

Country Link
US (1) US4265874A (OSRAM)
EP (1) EP0040899B1 (OSRAM)
JP (1) JPS56167617A (OSRAM)
AT (1) ATE9267T1 (OSRAM)
DE (1) DE3165901D1 (OSRAM)
DK (1) DK152482C (OSRAM)
ES (2) ES267593Y (OSRAM)
GR (1) GR73519B (OSRAM)
IE (1) IE51216B1 (OSRAM)
NZ (1) NZ196561A (OSRAM)
PT (1) PT72796B (OSRAM)

Families Citing this family (740)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
US4670578A (en) * 1983-08-29 1987-06-02 Merck & Co., Inc. Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
EP0137364A3 (en) * 1983-09-23 1986-10-22 Merck & Co. Inc. Suppository form of an osmotic therapeutic system
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
GB2150434B (en) * 1983-12-01 1987-11-04 Alza Corp Constant rate release systems
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
DE3586445T2 (de) 1984-06-26 1993-01-14 Merck & Co Inc Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
EP0318066B1 (en) 1987-09-22 1992-07-29 Merck & Co. Inc. Aryl-substituted thiophene 3-ols, derivatives and analogs, as lipoxygenase inhibitors
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
CH675537A5 (OSRAM) * 1988-03-25 1990-10-15 Ciba Geigy Ag
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5089530A (en) 1990-08-03 1992-02-18 Merck & Co., Inc. Novel fermentation product with antiparasitic activity
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5639782A (en) * 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
ES2152952T3 (es) 1992-07-13 2001-02-16 Millennium Pharm Inc 2,5-diaril tetrahidro-tiofenos, -furanos y analogos para el tratamiento de problemas inflamatorios e inmunes.
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2220451A1 (en) * 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US6372713B1 (en) 1995-09-08 2002-04-16 The Board Of Trustees Of Northwestern University Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en) * 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
JP2002511837A (ja) 1996-09-10 2002-04-16 メデイノックス，インコーポレイテッド ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
US5858402A (en) * 1997-02-11 1999-01-12 Medinox, Inc. Methods for in vivo reduction of cyanide levels and compositions useful therefor
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
CA2306096A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
US6287605B1 (en) * 1998-04-17 2001-09-11 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treatment and prevention of HIV-1 infection
WO1999058640A2 (en) 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
WO2000009118A1 (en) 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
WO2000041731A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Reverse gene therapy
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
AU4803800A (en) 1999-04-27 2000-11-10 Trustees Of The University Of Pennsylvania, The Compositions, methods, and kits relating to LTiGTresistinLT/iGT
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7160694B2 (en) 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US6964854B1 (en) * 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
DE60041880D1 (de) 1999-10-08 2009-05-07 Taiji Biomedical Inc Verfahren zur verbesserung der chemotherapie
JP4754143B2 (ja) 1999-10-12 2011-08-24 ケモセントリックス， インコーポレイテッド ケモカインレセプター
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
JP3417370B2 (ja) 1999-12-09 2003-06-16 株式会社村田製作所 非可逆回路素子及び通信機装置
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
JP2001320205A (ja) 2000-03-02 2001-11-16 Murata Mfg Co Ltd 非可逆回路素子および通信装置
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ATE339963T1 (de) * 2000-04-07 2006-10-15 Univ Pennsylvania Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US7087632B2 (en) * 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
AU2001275043A1 (en) 2000-05-31 2001-12-11 Drugtech Corporation Mineral supplement
AU2001269803A1 (en) * 2000-06-20 2002-01-02 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
AU2001290629A1 (en) * 2000-09-07 2002-03-22 Boehringer Ingelheim International G.M.B.H Heat shock response and virus replication
CA2460042C (en) * 2000-09-26 2012-05-08 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US20040102367A1 (en) * 2001-02-23 2004-05-27 Gage Fred H Gene expression system based on chimeric receptors
US20030166063A1 (en) * 2001-03-05 2003-09-04 Harris Robert B. High level insect expression of rage proteins
CN1494425B (zh) * 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
CN1157388C (zh) * 2001-05-29 2004-07-14 北京大学 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
RU2259825C9 (ru) 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
AU2002322515A1 (en) * 2001-07-17 2003-03-03 Keith Choate Compositions, methods, and kits related to treating and diagnosing hypertension
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
WO2003015757A1 (en) * 2001-08-16 2003-02-27 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
WO2003018062A1 (en) * 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
US20030069071A1 (en) * 2001-09-28 2003-04-10 Tim Britt Entertainment monitoring system and method
RU2321593C9 (ru) 2001-10-19 2008-06-20 Изотехника Инк. Синтез аналогов циклоспорина
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
HUP0402309A3 (en) 2001-12-21 2008-09-29 Novo Nordisk As Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
JP4481011B2 (ja) * 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
JP4570878B2 (ja) 2002-04-11 2010-10-27 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1503754B1 (en) * 2002-04-19 2005-11-23 Yissum Research Development Company, of The Hebrew University of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
JP2005531544A (ja) * 2002-05-06 2005-10-20 ワシントン・ユニバーシティ Ｅｇｆｒ経路の抑制による緑内障およびｎｏｓ−２発現により媒介される他の状態の治療方法
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
AU2003236500B9 (en) 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
EP1558585B1 (en) 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
WO2004037206A2 (en) * 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
EP1558250A4 (en) 2002-10-30 2006-11-02 Merck & Co Inc GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
JP2006514101A (ja) 2002-11-08 2006-04-27 ノボ・ノルデイスク・エー／エス 肥満症の治療のための安全な化学的脱共役剤
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7420055B2 (en) * 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) * 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
DE60314175T2 (de) * 2002-11-18 2008-01-24 Chemocentryx Inc., Mountain View Arylsulfonamide
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
KR100772297B1 (ko) * 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
MXPA05006653A (es) 2002-12-20 2005-09-30 Arakis Ltd Benzoxazocinas novedosas y sus usos terapeuticos.
MXPA05006507A (es) * 2002-12-20 2006-02-17 Chemocentryx Inhibidores de ccxckr2 expresado en tumor humano.
WO2004062597A2 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
CA2519234A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
EP1618090A1 (en) 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
KR20120062863A (ko) * 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
EP2087905A2 (en) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
US8071535B2 (en) * 2003-09-12 2011-12-06 The Regents Of The University Of California Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
MXPA06006837A (es) * 2003-12-15 2006-09-04 Theramex Derivados de 1-n-fenil-amino-ih-imidazol y composiciones farmaceuticas que los contienen.
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
EA200601743A1 (ru) 2004-03-19 2007-08-31 Йел Юниверсити Выделенный полипептид реналазы и его применение
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CA2568622C (en) 2004-06-01 2016-01-26 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
EP1765328B1 (en) 2004-06-14 2011-11-23 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
WO2006002381A1 (en) * 2004-06-24 2006-01-05 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
US8507411B2 (en) * 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
EP1765785B1 (en) * 2004-07-02 2009-07-08 Allergan, Inc. Prostaglandin analogs
JP2008508882A (ja) * 2004-08-03 2008-03-27 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及び使用方法
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP2494992A1 (en) 2004-08-24 2012-09-05 Merck Sharp & Dohme Corp. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
KR20070054246A (ko) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
WO2006039252A2 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Compositions and methods for treating ophthalmic diseases
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7612082B2 (en) * 2004-10-28 2009-11-03 Allergan, Inc. Prostaglandin EP4 antagonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
CA2593545A1 (en) * 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20060173019A1 (en) 2005-01-14 2006-08-03 Solomon Ungashe Heteroaryl sulfonamides and CCR2
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
ES2434852T3 (es) * 2005-04-21 2013-12-17 Chemocentryx, Inc. Anticuerpos que se unen a CCX-CKR2
CN101166527A (zh) 2005-04-27 2008-04-23 艾尼纳制药公司 用于治疗肥胖症和糖尿病以及其相关病况和用于治疗可通过增加血液glp-1含量改善的病况的组合疗法
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
CA2609402C (en) 2005-05-23 2014-10-21 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
CN101505746A (zh) * 2005-06-17 2009-08-12 迪纳米斯治疗公司 炎症的治疗方法
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
MX2007016270A (es) 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ATE518853T1 (de) 2005-08-12 2011-08-15 Schering Corp Verbindungen zur behandlung entzündlicher erkrankungen
EP1924606A4 (en) 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
JP5259408B2 (ja) 2005-08-29 2013-08-07 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリン類縁体とその使用方法
AU2006289651B2 (en) 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
AU2006306228A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
DE602006018057D1 (de) 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
WO2007073555A1 (en) * 2005-12-20 2007-06-28 Gilead Colorado, Inc. Use of 4, 7-dihydrothieno [2, 3-b] pyridine compounds in the treatment of cardiovascular diseases
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
WO2007098240A2 (en) * 2006-02-21 2007-08-30 Astrum Therapeutics Pty. Ltd. Compositions to reduce blood glucose levels and treat diabetes
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
EP1996546B1 (en) 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20070225246A1 (en) * 2006-03-27 2007-09-27 Denu John M O-acetyl-ADP-ribose non-hydrolyzable analogs
SG10201404220TA (en) * 2006-04-11 2014-10-30 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
ES2437997T3 (es) 2006-04-14 2014-01-15 Prana Biotechnology Limited Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7476755B2 (en) 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
GEP20115140B (en) 2006-05-09 2011-01-10 Merck Sharp And Dome Corp Substituted spirocyclic cgrp receptor antagonists
US7547727B2 (en) 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
DK2035390T3 (en) 2006-07-05 2016-01-04 Merial Inc 1-aryl-5-alkylpyrazolderivatforbindelser, methods of making and methods of use thereof
AU2007272683B2 (en) 2006-07-10 2012-08-23 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
AU2007275873B2 (en) 2006-07-14 2012-06-14 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2076525A2 (en) * 2006-10-06 2009-07-08 Wisconsin Alumni Research Foundation Colchicine neoglycosides and methods for their synthesis and use
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
WO2008073752A2 (en) 2006-12-11 2008-06-19 Allergan, Inc. Cyclobutyl derivatives for the treatment of glaucoma
GB0624757D0 (en) 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
WO2008077092A2 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
CA2673616A1 (en) 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
WO2008082217A1 (en) * 2006-12-28 2008-07-10 Lg Electronics Inc. Ice making system and method for ice making of refrigerator
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
WO2008101060A1 (en) * 2007-02-14 2008-08-21 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
JP2010520236A (ja) 2007-02-28 2010-06-10 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリンアナログとその使用法
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
PL2639228T3 (pl) 2007-05-15 2017-01-31 Merial, Inc. Związki aryloazol-2-ilocyjanoetyloaminowe, sposób ich wytwarzania oraz sposób ich zastosowania
HUE032273T2 (en) 2007-05-22 2017-09-28 Chemocentryx Inc 3-Imidazolyl-pyrazolo [3,4-b] pyridines
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
GB2454290B (en) 2007-08-07 2009-09-30 Prosarix Ltd Novel serotonergic modulators
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
WO2009052116A1 (en) 2007-10-15 2009-04-23 The Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8389485B2 (en) * 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
AU2009225747A1 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1P3 receptor inhibitors for treating inflammation
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
AU2009239381A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2291368B1 (en) * 2008-04-24 2012-12-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2731279A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
EP2285790A1 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic compounds
BRPI0912342A2 (pt) * 2008-05-09 2015-10-06 Allergan Inc tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados
US7981887B2 (en) * 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
JP2011519937A (ja) * 2008-05-09 2011-07-14 アラーガン インコーポレイテッド 治療用ｎ‐アリールまたはｎ‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体
WO2009137343A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
US8530471B2 (en) * 2008-05-09 2013-09-10 Allergan, Inc. Therapeutic cyclopentane derivatives
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
WO2009146255A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin produgs as hypotensive agents
US8252788B2 (en) * 2008-05-20 2012-08-28 Allergan, Inc. Therapeutic compounds
EP2285775B1 (en) * 2008-05-20 2017-03-22 Allergan, Inc. Lactams and their use in the treatment of inter alia ocular hypertension or baldness
AU2009257733A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
WO2010012650A1 (en) 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EA019606B1 (ru) 2008-11-14 2014-04-30 Мериал Лимитед Арилоазол-2-илцианоэтиламино соединения противопаразитарного действия, обогащенные одним из энантиомеров
EP2186521A1 (en) 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
EP2550962B1 (en) 2008-11-19 2019-10-30 Boehringer Ingelheim Animal Health USA Inc. Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
TWI457347B (zh) 2008-12-04 2014-10-21 Merial Ltd 二聚合的阿佛菌素（ａｖｅｒｍｅｃｔｉｎ）及密倍脈心（ｍｉｌｂｅｍｙｃｉｎ）衍生物
EP3508477B1 (en) 2008-12-22 2021-11-10 ChemoCentryx, Inc. C5ar antagonists
PE20110924A1 (es) 2009-01-23 2011-12-24 Rigel Pharmaceuticals Inc Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
CA2752156A1 (en) 2009-02-13 2010-08-19 Daniel W. Gil 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2010093930A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
EA021076B1 (ru) 2009-02-24 2015-03-31 Мерк Шарп Энд Домэ Корп. Производные индола в качестве антагонистов рецептора crth2
GB0904044D0 (en) 2009-03-09 2009-04-22 Sosei R & D Ltd The treatment of inflammatory disorders and pain
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
WO2010114997A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP3195896A1 (en) 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
HUE052685T2 (hu) 2009-05-19 2021-05-28 Neuroderm Ltd Dopa-dekarboxiláz inhibitorok folyamatos adagolására szolgáló készítmények
BR112012001047A2 (pt) * 2009-07-17 2019-09-24 Allergan Inc composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos
EP2459195A1 (en) * 2009-07-28 2012-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
IN2012DN01846A (OSRAM) 2009-08-11 2015-08-21 Allergan Inc
BR112012003573A2 (pt) * 2009-08-20 2016-03-08 Twi Biotechnology Inc métodos para determinar uma eficácia de um composto para o tratamento de diabete e para diagnosticar diabete.
CA2772354A1 (en) 2009-08-26 2011-03-10 Daniel W. Gil Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
CA2771352A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9889182B2 (en) 2009-09-15 2018-02-13 The Regents Of The University Of California Assisted enzyme replacement therapy
CN102574789B (zh) 2009-09-21 2014-12-10 凯莫森特里克斯股份有限公司 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
BR112012012391A2 (pt) 2009-11-25 2020-10-20 Cytometix, Inc. análogos de ácido araquidônico e métodos para tratamento analgésico utilizando o mesmo
ES2546100T3 (es) 2009-12-04 2015-09-18 Merial, Inc. Compuestos pesticidas bis-organosulfurados
DK3078664T3 (da) 2009-12-17 2019-05-13 Merial Inc Antiparasitiske dihydroazol-sammensætninger
BR112012014933B1 (pt) 2009-12-17 2020-10-27 Merial, Inc. composições que compreendem compostos lactonas macrocíclicas e spirodioxepinoindóis
JP5540454B2 (ja) * 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
US8299068B2 (en) * 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
NZ602111A (en) 2010-02-03 2014-10-31 Pharma Two B Ltd Extended release formulations of rasagiline and uses thereof
GB201002530D0 (en) 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
TWI510241B (zh) * 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
SG184243A1 (en) 2010-03-30 2012-10-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20110288093A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
EP2560643A1 (en) 2010-04-20 2013-02-27 Institute for OneWorld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
US20130116284A1 (en) 2010-05-10 2013-05-09 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP5902676B2 (ja) 2010-05-26 2016-04-13 ブイティーブイ セラピューティクス リミティド ライアビリティ カンパニー グルコキナーゼ活性化因子と組み合わせたメトホルミンの使用、及びメトホルミン及びグルコキナーゼ活性化因子を含む組成物
US9193989B2 (en) 2010-06-18 2015-11-24 Taiho Pharmaceutical Co., Ltd. PRPK-TPRKB modulators and uses thereof
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US8492424B2 (en) 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
US9714238B2 (en) 2010-07-02 2017-07-25 Allergan, Inc. Therapeutic agents for ocular hypertension
NZ605709A (en) 2010-07-02 2014-08-29 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
BR112013002846A2 (pt) 2010-08-05 2016-06-07 Conrig Pharma Aps derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
KR102013086B1 (ko) 2010-08-16 2019-08-21 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
ES2485373T3 (es) 2010-08-20 2014-08-13 Allergan, Inc. Compuestos que actúan en múltiples receptores de prostaglandina proporcionando una respuesta anti-inflamatoria general
WO2012032513A1 (en) 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
WO2012032524A1 (en) 2010-09-09 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Near infrared fluorescent particles and uses thereof
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
SI2627328T1 (sl) 2010-10-15 2017-01-31 Contera Pharma Aps Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
US20130315934A1 (en) 2010-10-28 2013-11-28 Yale University Methods and Compositions for Assessing and Treating Cancer
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
CA2818563C (en) 2010-11-16 2019-11-12 Merial Limited Monensin derivatives for the treatment and prevention of protozoal infections.
US9308255B2 (en) 2010-11-24 2016-04-12 Yale University Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury
WO2012070040A1 (en) 2010-11-26 2012-05-31 Technion Research And Development Foundation Ltd Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
WO2012074785A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
GB201020860D0 (en) 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
HRP20190096T1 (hr) 2010-12-15 2019-02-22 Contravir Pharmaceuticals, Inc. Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
SG191855A1 (en) 2011-01-07 2013-08-30 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
MX339243B (es) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
US20120231069A1 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
DK2683385T3 (en) 2011-03-10 2018-09-17 Rigel Pharmaceuticals Inc 2,4-SUBSTITUTED PYRIMIDINE DIAMINES FOR DISKOID LUPUS USE
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US9127027B2 (en) 2011-04-06 2015-09-08 The Medical College Of Wisconsin, Inc. Epoxyeicosatrienoic acid analogs and methods of making and using the same
EP2694465A4 (en) 2011-04-08 2015-03-18 Univ Syddansk SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012143377A1 (en) 2011-04-18 2012-10-26 Max-Delbrück-Centrum für Molekulare Medizin Niclosamide for the treatment of cancer metastasis
AU2012250776B2 (en) 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR20140048881A (ko) 2011-05-09 2014-04-24 유니버시티 오브 버지니아 페이턴트 파운데이션 암 치료 조성물 및 방법
EP2714028A1 (en) 2011-05-27 2014-04-09 Allergan, Inc. D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
EP2714040A1 (en) 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
AU2012271562A1 (en) 2011-06-17 2014-01-30 Allergan, Inc. D -serine for the treatment of visual system disorders
WO2013003168A1 (en) 2011-06-27 2013-01-03 Merial Limited Novel insect-repellent coumarin derivatives, syntheses, and methods of use
ES2618813T3 (es) 2011-06-27 2017-06-22 Merial, Inc. Compuestos y composiciones de éter amido-piridílico y uso contra los parásitos
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
EP2736906B1 (en) 2011-07-25 2016-10-19 Allergan, Inc. N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EP2763540A4 (en) 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP2758377B1 (en) 2011-09-22 2017-08-02 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
US9096598B2 (en) 2011-10-03 2015-08-04 Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI480042B (zh) 2011-11-03 2015-04-11 Taiwan Liposome Co Ltd 疏水性喜樹鹼衍生物之醫藥組合物
BR112014011775A8 (pt) 2011-11-17 2017-07-11 Merial Ltd Composições compreendendo um aril pirazol e um imidazol substituído, métodos e usos dos mesmos
CN103202863A (zh) 2011-11-18 2013-07-17 善笙生物科技股份有限公司 一种用于预防或改善关节炎症状的药物组合物及其应用
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
CA2856831C (en) 2011-12-01 2020-02-18 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
EP2785719B1 (en) 2011-12-02 2017-11-08 Merial, Inc. Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6132851B2 (ja) 2011-12-21 2017-05-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
JP6124187B2 (ja) 2011-12-21 2017-05-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
CA2862263C (en) 2011-12-27 2016-09-06 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2966064A1 (en) 2011-12-27 2016-01-13 Allergan, Inc. Pyrazole-3-carboxylic acid compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
ES2832773T3 (es) 2012-01-06 2021-06-11 Anji Pharma Us Llc Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
EP2814485A4 (en) 2012-02-17 2015-08-26 Merck Sharp & Dohme DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
KR102083693B1 (ko) 2012-02-29 2020-03-02 케모센트릭스, 인크. Ccr9 길항제로써 피라졸-1-일 벤젠 술폰아미드
JP6231548B2 (ja) 2012-03-23 2017-11-15 マテオン セラピューティクス， インコーポレイテッド カテプシンの阻害のための組成物および方法
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP2015519309A (ja) 2012-04-16 2015-07-09 カネック ファーマ インコーポレイテッド Ｐｔｐ−１ｂインヒビター前駆体としての縮合芳香族ホスホナート誘導体
EP2838519B1 (en) 2012-04-17 2017-11-22 University College Dublin National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
US9388127B2 (en) 2012-04-17 2016-07-12 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
CN104411301B (zh) 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
US9296750B2 (en) 2012-05-09 2016-03-29 Merck Sharp & Dohme Corp. Spirolactam CGRP receptor antagonists
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20150368197A1 (en) 2012-06-21 2015-12-24 Radikal Therapeutics Ins. Compositions and methods for treatment of inflammatory diseases of the lung
US20140024621A1 (en) 2012-07-23 2014-01-23 Ms Therapeutics Limited Aminopyridine compounds and their uses
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
CN107184569A (zh) 2012-08-09 2017-09-22 迪纳米斯治疗公司 保持或改善对象健康、幸福和/或生理功能的方法
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
EP2895172B1 (en) 2012-09-12 2019-02-06 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
CN104822702B (zh) 2012-10-19 2019-07-30 Txp制药股份有限公司 α-MSH和γ-MSH类似物
US9938281B2 (en) 2012-11-16 2018-04-10 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
BR112015011441A2 (pt) 2012-11-20 2017-07-11 Merial Inc composições e compostos antihelmínticos e métodos de usos dos mesmos
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
JP6403688B2 (ja) 2013-01-21 2018-10-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 全身性抗炎症反応を提供する複数のプロスタグランジン受容体で作用する化合物
US20140213555A1 (en) 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and method for treating autoimmune diseases
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR20160005330A (ko) 2013-03-05 2016-01-14 라디칼 쎄라퓨틱스 인코포레이티드 다기능 질소산화물 유도체의 프로드럭 및 그의 용도
KR102209353B1 (ko) 2013-03-13 2021-01-29 뉴로덤 엘티디 파킨슨 병 치료 방법
AU2014239641B2 (en) 2013-03-14 2016-10-20 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SI2968297T1 (sl) 2013-03-15 2019-02-28 Verseon Corporation Multisubstituirane aromatske skupine kot inhibitorji serinske proteaze
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
US9051294B2 (en) 2013-04-30 2015-06-09 Allergan, Inc. Therapeutic agents
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
ES2769893T3 (es) 2013-07-02 2020-06-29 Ecoplanet Env Llc Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI622406B (zh) 2013-10-23 2018-05-01 善笙生物科技股份有限公司 來自牛樟芝菌絲體的化合物及混合物的用途
US9315486B2 (en) 2013-10-29 2016-04-19 Allergan, Inc. Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
NZ719916A (en) 2013-11-01 2017-09-29 Merial Inc Antiparasitic and pesticidal isoxazoline compounds
WO2015073344A1 (en) 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN105960237B (zh) 2013-12-02 2020-03-31 凯莫森特里克斯股份有限公司 Ccr6化合物
US9388153B2 (en) 2013-12-20 2016-07-12 Allergan, Inc. Secondary amines as therapeutic agents
WO2015113057A1 (en) 2014-01-27 2015-07-30 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3116475T3 (pl) 2014-03-13 2021-02-08 Neuroderm Ltd Kompozycje inhibitora dekarboksylazy dopa
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
AU2015249540B2 (en) 2014-04-22 2019-08-22 Txp Pharma Gmbh Peptide analogues with branched amino acid probe(s)
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
US9394273B2 (en) 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
CN106536518B (zh) 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
WO2015179815A1 (en) 2014-05-22 2015-11-26 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
KR101636758B1 (ko) * 2014-05-30 2016-07-06 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
KR20170010059A (ko) 2014-06-06 2017-01-25 알러간, 인코포레이티드 치료적 화합물로서 신규한 ep4 작용제
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
WO2016009341A1 (en) 2014-07-14 2016-01-21 Radikal Therapeutics Inc. Thioredoxin mimetic prodrugs and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US10954240B2 (en) 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
IL292655B2 (en) 2014-10-06 2024-03-01 Chemocentryx Inc CCR9 chemokine receptor inhibitor for use in a method for treating or reducing the development of inflammatory bowel diseases
BR112017011335A2 (pt) 2014-12-02 2018-02-20 Prana Biotechnology Limited compostos de 4h-pirido[1,2-a]pirimidin-4-ona
WO2016092546A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators
US9899696B2 (en) * 2015-01-21 2018-02-20 Lockheed Martin Advanced Energy Storage, Llc Solid buffer materials for electrolyte solutions and flow batteries utilizing same
PT3258962T (pt) 2015-02-20 2023-02-16 Univ Leland Stanford Junior Composições mistas de alergénios e métodos para a utilização das mesmas
KR102824411B1 (ko) 2015-02-27 2025-06-23 베르선 코포레이션 세린 프로테아제 저해제로서의 치환된 피라졸 화합물
SG11201707276PA (en) 2015-03-09 2017-10-30 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
MX379719B (es) 2015-05-20 2025-03-11 Boehringer Ingelheim Animal Health Usa Inc Compuestos depsipeptidicos como anthelmínticos.
JP6356364B1 (ja) 2015-05-20 2018-07-11 アムジエン・インコーポレーテツド Ａｐｊ受容体のトリアゾールアゴニスト
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CA2988086C (en) 2015-06-03 2023-09-19 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
DK3307296T3 (da) 2015-06-15 2021-12-13 Univ Leland Stanford Junior Timp2 til anvendelse til behandling af aldringsassocierede tilstande
CA2988593C (en) 2015-06-16 2023-10-24 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
ES2858551T3 (es) 2015-06-16 2021-09-30 Atxa Therapeutics Ltd Antagonistas del receptor de tromboxano
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
JP6731427B2 (ja) 2015-06-30 2020-07-29 ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
WO2017007835A1 (en) 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for nanoemulsion vaccine formulations
WO2017025951A1 (en) 2015-08-10 2017-02-16 Ramot At Tel-Aviv University Ltd. Pillararenes and uses thereof
US11497813B2 (en) 2015-11-02 2022-11-15 Biovinc, Llc Bortezomib conjugates and methods using same
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
WO2017079260A1 (en) 2015-11-02 2017-05-11 University Of Rochester Phosphonate-chloroquine conjugates and methods using same
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
ES2985738T3 (es) 2016-01-20 2024-11-07 Chemocentryx Inc Compuestos de 2-oxindol
JP7003045B2 (ja) 2016-02-11 2022-02-04 シェヴィオン モデハイ 神経変性の治療のための方法及び医薬組成物
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2017153977A1 (en) 2016-03-08 2017-09-14 Salzman Lovelace Investments, Ltd. Solid formulations of resolvins and uses thereof
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
EP4094778B1 (en) 2016-06-03 2024-05-15 Novacyte Therapeutics Company.,LTD Polymer linkers and their uses
ES2979332T3 (es) 2016-06-27 2024-09-25 Chemocentryx Inc Compuestos inmunomoduladores
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
CN110381738B (zh) 2016-10-14 2021-07-16 勃林格殷格翰动物保健美国公司 农药的和杀寄生物的乙烯基异噁唑啉化合物
JP7414525B2 (ja) 2016-11-03 2024-01-16 ウー，ローレンス，アイ． クロファラビンのプロドラッグ
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
BR112019009977A2 (pt) 2016-11-16 2019-08-27 Boehringer Ingelheim Animal Health Usa Inc compostos depsipeptídicos anti-helmínticos
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP4134080B1 (en) 2016-11-23 2024-11-13 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
EP4095135A1 (en) 2016-12-14 2022-11-30 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
AR111464A1 (es) 2017-04-14 2019-07-17 Contravir Pharmaceuticals Inc Terapia combinada para el tratamiento de infecciones virales
DE202017002464U1 (de) 2017-05-09 2017-06-12 St. Lotus Biotech Corp. Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
US11484543B2 (en) 2017-05-18 2022-11-01 The Rockefeller University Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
KR102704242B1 (ko) 2017-06-20 2024-09-09 임브리아 파마슈티칼스, 인크. 심장 대사의 효율을 증가시키기 위한 조성물 및 방법
JP7198269B2 (ja) 2017-08-08 2022-12-28 ケモセントリックス，インコーポレイティド 大員環免疫調節剤
ES2944616T3 (es) 2017-08-14 2023-06-22 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol-isoxazolina plaguicidas y parasiticidas
WO2019038764A1 (en) 2017-08-23 2019-02-28 Gavish-Galilee Bio Applications Ltd. COMPOSITIONS AND METHODS FOR TREATING AEROSCLASTER CARDIOVASCULAR DISEASE
JP7453139B2 (ja) 2017-09-25 2024-03-19 ケモセントリックス，インコーポレイティド ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
WO2019089534A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019104316A1 (en) 2017-11-27 2019-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
SG11202005799XA (en) 2017-12-22 2020-07-29 Chemocentryx Inc DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
MA51331A (fr) 2017-12-22 2020-10-28 Chemocentryx Inc COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
WO2019141957A1 (en) 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
JP2021513512A (ja) 2018-02-05 2021-05-27 シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｉｏｎｏｖａ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
US11583545B2 (en) 2018-02-08 2023-02-21 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
CA3091088A1 (en) 2018-02-13 2019-08-22 Beetlebung Pharma Ltd. Cannabinoid derivatives and conjugates and uses thereof
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
US10982210B2 (en) 2018-03-02 2021-04-20 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
EP3552605A1 (en) 2018-04-11 2019-10-16 Univerzita Palackého V Olomouchi Mcoppb for use as medicament
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
MX2020012805A (es) 2018-05-29 2021-02-15 Cersci Therapeutics Inc Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
US20190374607A1 (en) 2018-06-08 2019-12-12 The Medical College Of Wisconsin, Inc. Methods of treating vascular leakage using cxcl12 peptides
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
EP3820870A1 (en) 2018-07-09 2021-05-19 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
TWI869058B (zh) 2018-07-27 2025-01-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US12030872B2 (en) 2018-10-31 2024-07-09 Merck Sharp & Dohme Llc N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US11773066B2 (en) 2018-11-20 2023-10-03 Boehringer Ingelheim Animal Health USA Inc. Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
CN119285648A (zh) 2019-03-19 2025-01-10 勃林格殷格翰动物保健有限公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
US12319671B2 (en) 2019-06-06 2025-06-03 Merck Sharp & Dohme Llc 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
JP7693644B2 (ja) 2019-07-08 2025-06-17 リゾルート，インコーポレイティド 血漿カリクレイン阻害薬の調製プロセス
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
JP7682155B2 (ja) 2019-08-08 2025-05-23 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
MX2022001890A (es) 2019-08-14 2022-04-26 Rigel Pharmaceuticals Inc Metodo para bloquear o mejorar el sindrome de liberacion de citocinas.
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EP4045036A4 (en) 2019-10-16 2023-11-15 ChemoCentryx, Inc. Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CA3154247A1 (en) 2019-10-25 2021-04-29 Mitchell H. KEYLOR N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CN118908882A (zh) 2019-11-08 2024-11-08 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
US20230149400A1 (en) 2020-03-27 2023-05-18 Aclaris Therapeutics, Inc. Methods and compositionsfor treating viral infections
CN115484944A (zh) 2020-03-31 2022-12-16 坎莫森特里克斯公司 使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法
JP2023522985A (ja) 2020-04-23 2023-06-01 エーゼットセラピーズ， インコーポレイテッド Ｈｌａクラスｉ ｍｈｃの細胞切除
EP3901160A1 (en) 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
US20230150984A1 (en) 2020-04-24 2023-05-18 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
CN115997016A (zh) 2020-04-27 2023-04-21 西克斯福德生物科学有限公司 包含具有模块化官能团的核酸纳米颗粒的组合物
CA3176169A1 (en) 2020-04-30 2021-11-04 Annette M. TOBIA Compositions and methods for treating cytokine storms
IL298501A (en) 2020-05-28 2023-01-01 Aztherapies Inc Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases
CR20220665A (es) 2020-05-29 2023-07-19 Boehringer Ingelheim Pharma Compuestos heterocíclicos como anthelmínticos
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
AU2021304808A1 (en) 2020-07-07 2023-02-09 Atxa Therapeutics Limited Thromboxane receptor antagonist formulations
EP4182326A1 (en) 2020-07-17 2023-05-24 Université de Bretagne Occidentale New glycolipids and use thereof as sk3 ion channel modulators
JP2023535744A (ja) 2020-07-29 2023-08-21 アラーガン ファーマシューティカルズ インターナショナル リミテッド 片頭痛の治療
WO2022029275A1 (en) 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
AU2021322736A1 (en) 2020-08-07 2023-03-02 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
BR112023002608A2 (pt) 2020-08-12 2023-05-09 Txp Pharma Ag Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
KR20230090336A (ko) 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
EP4236950A4 (en) 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB202017251D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Neurodegenerative treatment
GB202017255D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US12403153B2 (en) 2020-12-18 2025-09-02 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
US20240299318A1 (en) 2021-02-08 2024-09-12 Bausch Health Ireland Limited Amiselimod for preventing, treating or ameliorating ulcerative colitis
WO2022184685A1 (en) 2021-03-01 2022-09-09 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2022254425A1 (en) 2021-05-31 2022-12-08 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
US20240382511A1 (en) 2021-06-17 2024-11-21 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
WO2023012182A1 (en) 2021-08-02 2023-02-09 Nuvamid Sa Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023023532A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
US12350259B2 (en) 2021-09-27 2025-07-08 Allergan Pharmaceuticals International Limited Methods of treating migraine
JP2024537329A (ja) 2021-10-12 2024-10-10 ベータヴァイヴ・リミテッド 糖尿病及び関連する代謝性疾患を処置するためのペプチド及び断片
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL319372A (en) 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
PE20251547A1 (es) 2022-10-25 2025-06-05 Merck Sharp And Dohme Llc Enlazadores-cargas utiles de adc derivados de exatecan, composiciones farmaceuticas, y usos de los mismos
EP4633681A1 (en) 2022-12-14 2025-10-22 Merck Sharp & Dohme LLC Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
US12091400B2 (en) 2023-01-20 2024-09-17 Epics Therapeutics Piperidine derivatives as METTL3 inhibitors
WO2024194175A1 (en) 2023-03-17 2024-09-26 Atmosr Adenine derivatives as hsp90 inhibitors
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
WO2025011733A1 (en) 2023-07-07 2025-01-16 Nuvamid Sa Nicotinamide mononucleotide and derivatives thereof and use thereof in the treatment and prevention of polycythemia
US20250057848A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
GB2636364A (en) 2023-12-07 2025-06-18 Aramune Tech Limited Arabinogalactan
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2025176994A1 (en) 2024-02-20 2025-08-28 Analytical Services For Art & Archaeology (Scotland) Ltd Composition and method of use
WO2025219976A1 (en) 2024-04-19 2025-10-23 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases
GB202405650D0 (en) 2024-04-22 2024-06-05 Royal College Surgeons Ireland Hdac6 protacs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536155A (en) * 1895-03-19 Pill or tablet
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US3062715A (en) * 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
GB917456A (en) * 1958-10-30 1963-02-06 Casco Lab Inc Suppository composition and preparation thereof
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3136692A (en) * 1961-06-30 1964-06-09 Strong Cobb Arner Inc Effervescent composition containing polyvinylpyrrolidone
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
FR5391M (OSRAM) * 1965-11-04 1967-10-23
GB1123316A (en) * 1966-12-09 1968-08-14 Wynlit Pharmaceuticals Trust R Improvements in suppositories
US3495001A (en) * 1968-05-27 1970-02-10 Miles Lab Effervescent compositions of acetylsalicylic acid
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
US3764668A (en) * 1970-09-30 1973-10-09 Interx Research Corp Compositions of salts of salicylamide
US3676549A (en) * 1970-09-30 1972-07-11 Alza Corp Administration of alkali metal salts of salicylamide
GB1359614A (en) * 1971-04-06 1974-07-10 Dev Et De Rech Soc Fr De Method for the manufacture of effervescent tablets
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

Also Published As

Publication number Publication date
DE3165901D1 (en) 1984-10-18
PT72796B (fr) 1982-03-30
US4265874A (en) 1981-05-05
JPH044293B2 (OSRAM) 1992-01-27
DK152482C (da) 1988-08-01
EP0040899A2 (en) 1981-12-02
IE51216B1 (en) 1986-11-12
DK184681A (da) 1981-10-26
ES510822A0 (es) 1983-06-16
ES8307092A1 (es) 1983-06-16
IE810765L (en) 1981-10-25
PT72796A (fr) 1981-05-01
ES267593Y (es) 1983-11-16
EP0040899A3 (en) 1982-08-11
NZ196561A (en) 1983-05-10
DK152482B (da) 1988-03-07
EP0040899B1 (en) 1984-09-12
ES267593U (es) 1983-05-16
ATE9267T1 (de) 1984-09-15
JPS56167617A (en) 1981-12-23

Similar Documents

Publication Publication Date Title
GR73519B (OSRAM)
ATE280317T1 (de) Abgabevorrichtung für additive
US4801093B1 (en) Push-nipple for medical sprayer
EP0684796A4 (en) CONTAINER FOR BLOOD STORAGE AND METHOD OF USE.
JPS5793065A (en) Permeation apparatus having hydrogel drive member
ES8705240A1 (es) Dispositivo osmotico para la administracion controlada de unagente benefico a un ambiente de utilizacion
NZ290045A (en) Osmotic delivery device includes a fluid impermeable and fluid permeable portion and a head space spaced from an exit passageway in the device
AU1926795A (en) Gas delivery apparatus and compositions for infusion
ES257490U (es) Bolsa de inyeccion de fluido
ES8503499A1 (es) Dispositivo osmotico
GB1509564A (en) Emitter apparatus for dispensing fluid
ES288293U (es) Dispositivo para el equilibrado de la presion para contenedor de transporte.
UA7225A1 (uk) Дозуючий пристрій, розташований у колпачку аерозольної ємкості
ES2134908T3 (es) Difusor con brida y retenedor de camara de aire para recipiente a presion.
AU3160999A (en) Dispensing means
JPS5791773A (en) Method for sending paint to roller type painting apparatus under pressure
EP0704229A3 (de) Verfahren und Vorrichtung zum impulsförmigen Austragen einer Flüssigkeit, insbesondere eines Feuerlöschmittels
GB1157970A (en) Improvements in or relating to Aerosol Dispensers